New hope for advanced liver cancer: experimental drug faces off against standard therapy
NCT ID NCT07300488
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tests a new drug called pracytarabine against a standard drug (regorafenib) in 60 adults with advanced liver cancer that has not responded to previous targeted therapy and immunotherapy. The goal is to see if pracytarabine helps patients live longer or slows cancer growth. Participants must be 18-75 years old with good liver function and an expected survival of at least 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, 211100, China
Conditions
Explore the condition pages connected to this study.